Last updated: 20 July 2019 at 2:39am EST

Andrew L Lux Net Worth




The estimated Net Worth of Andrew L Lux is at least $2.4 millió dollars as of 17 March 2017. Andrew Lux owns over 20,000 units of Atricure Inc stock worth over $2,302,344 and over the last 13 years Andrew sold ATRC stock worth over $94,563.

Andrew Lux ATRC stock SEC Form 4 insiders trading

Andrew has made over 3 trades of the Atricure Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Andrew exercised 20,000 units of ATRC stock worth $125,400 on 17 March 2017.

The largest trade Andrew's ever made was exercising 20,000 units of Atricure Inc stock on 17 March 2017 worth over $125,400. On average, Andrew trades about 1,042 units every 59 days since 2012. As of 17 March 2017 Andrew still owns at least 85,589 units of Atricure Inc stock.

You can see the complete history of Andrew Lux stock trades at the bottom of the page.



What's Andrew Lux's mailing address?

Andrew's mailing address filed with the SEC is 6217 CENTRE PARK DRIVE, , WEST CHESTER, OH, 45069.

Insiders trading at Atricure Inc

Over the last 19 years, insiders at Atricure Inc have traded over $52,789,242 worth of Atricure Inc stock and bought 666,621 units worth $5,937,195 . The most active insiders traders include Scott William Drake, Group I, Llc Donoghue Danie... és Management Group Viii L L C.... On average, Atricure Inc executives and independent directors trade stock every 24 days with the average trade being worth of $548,410. The most recent stock trade was executed by Maggie Yuen on 15 August 2024, trading 3,500 units of ATRC stock currently worth $84,245.



What does Atricure Inc do?

atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage exclusion system products are the most widely sold laa management devices worldwide, with more than 100,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure.



Complete history of Andrew Lux stock trades at Atricure Inc

Az érdekelt
Trans.
Tranzakció
Teljes ár
Andrew L Lux
V.P. és Operatív vezérigazgató
Opció Gyakorlat $125,400
17 Mar 2017
Andrew L Lux
V.P. és Operatív vezérigazgató
Eladás $94,563
7 Dec 2016
Andrew L Lux
V.P. és Operatív vezérigazgató
Megvenni $8,390
13 Mar 2013


Atricure Inc executives and stock owners

Atricure Inc executives and other stock owners filed with the SEC include: